Document is current
Any future updates will be listed below
-
Authors
Götze, Thorsten O.
Piso, Pompiliu
Lorenzen, Sylvie
Bankstahl, Ulli S. https://orcid.org/0000-0002-4432-5507
Pauligk, Claudia
Elshafei, Moustafa
Amato, Giuseppe
Reim, Daniel
Bechstein, Wolf O.
Königsrainer, Alfred
Mönig, Stefan P.
Rau, Beate
Schwarzbach, Matthias
Al-Batran, Salah-Eddin
-
Funding
Funding for this research was provided by:
deutsche krebshilfe (70113137)
- License Information
-
More Information
Article History
Received: 29 July 2021
Accepted: 11 October 2021
First Online: 29 October 2021
Declarations
:
: The study protocol was approved by the responsible lead ethics committee of the Landesärtzekammer Hessen, Hanauer Landstr. 152, 60314 Frankfurt am Main, Germany, responsible for the Krankenhaus Nordwest Frankfurt- UCT (University Cancer Center) on July 27th, 2020 under the identification number 2020-1709-fAM. A trial amendment was approved by the responsible lead ethics committee on May 18th, 2021, Version 1.2. The study has been registered on the website under the identification number NCT04447352. The PREVENT study complies with the Declaration of Helsinki rules, the principles of Good Clinical Practice guidelines and the Data Protection Act. The trial will also be carried out in compliance to local legal and regulatory requirements. For each patient to be enrolled into the study, obtaining written informed consent prior to inclusion into the study is essential.
: “Not applicable”.
: The authors declare that they have no competing interests.
